NEA Management Company, LLC - Q1 2018 holdings

$2.25 Billion is the total value of NEA Management Company, LLC's 43 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 42.9% .

 Value Shares↓ Weighting
TSRO BuyTESARO INC$595,431,000
-30.1%
10,420,555
+1.4%
26.49%
-24.9%
CRSP BuyCRISPR THERAPEUTICS AGnamen akt$159,275,000
+110.6%
3,484,464
+8.2%
7.08%
+126.1%
ADAP BuyADAPTIMMUNE THERAPEUTICS PLCadr$149,725,000
+86.4%
13,332,611
+10.9%
6.66%
+100.1%
SYBX BuySYNLOGIC INC$39,672,000
+7.1%
4,229,410
+10.7%
1.76%
+15.0%
RARX BuyRA PHARMACEUTICALS INC$29,171,000
-1.8%
5,493,636
+57.2%
1.30%
+5.5%
GNCA NewGENOCEA BIOSCIENCES INC$26,250,00025,000,000
+100.0%
1.17%
CTIC NewCTI BIOPHARMA CORP$14,625,0003,750,000
+100.0%
0.65%
AFMD BuyAFFIMED NV$9,507,000
+88.0%
5,138,888
+32.1%
0.42%
+102.4%
TCON BuyTRACON PHARMACEUTICALS INC$7,975,000
-13.7%
3,467,181
+25.7%
0.36%
-7.3%
AYTU NewAYTU BIOSCIENCE INC$29,00044,908
+100.0%
0.00%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-05-10
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
GLYCOMIMETICS INC41Q1 20247.6%
AURINIA PHARMACEUTICALS INC40Q2 20245.0%
CHAMPIONS ONCOLOGY INC36Q2 20241.2%
LEXICON PHARMACEUTICALS INC35Q2 20242.0%
ADAPTIMMUNE THERAPEUTICS PLC34Q2 20249.3%
CRISPR THERAPEUTICS AG31Q2 202411.2%
TREVENA INC31Q3 20213.3%
AKARI THERAPEUTICS PLC31Q2 20230.3%
ARDELYX INC29Q3 202111.9%
VERONA PHARMA PLC29Q2 20249.0%

View NEA Management Company, LLC's complete holdings history.

Latest filings
TypeFiled
N-PX2024-08-30
13F-HR2024-08-14
13F-HR2024-05-15
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-11
13F-HR2023-05-15
13F-HR2023-02-10
13F-HR2022-11-14
13F-HR2022-08-15

View NEA Management Company, LLC's complete filings history.

Compare quarters

Export NEA Management Company, LLC's holdings